ArticleBiomaterials2010
The contribution of plasmid design and release to in vivo gene expression following delivery from cationic polymer modified scaffolds.
Article in Biomaterials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 52 citations in OpenAlex.
- Physical and mechanical cues affecting biomaterial-mediated plasmid DNA delivery: insights into non-viral delivery systems.Journal, genetic engineering & biotechnology · 2021Review
- It's All in the Delivery: Designing Hydrogels for Cell and Non-viral Gene Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Bone Regeneration Using Gene-Activated Matrices.The AAPS journal · 2017Review
- Gene delivery strategies to promote spinal cord repair.Biomarker insights · 2015Review
- Modulation of leukocyte infiltration and phenotype in microporous tissue engineering scaffolds via vector induced IL-10 expression.Biomaterials · 2014Article
- Matrix-based gene delivery for tissue repair.Current opinion in biotechnology · 2013Review
- PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.Tissue engineering. Part A · 2013Article
- Biomaterial Scaffolds for Controlled, Localized Gene Delivery of Regenerative Factors.Advances in wound care · 2013Review
- Porous scaffolds support extrahepatic human islet transplantation, engraftment, and function in mice.Cell transplantation · 2013Article
- Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis.Biomaterials · 2012Article
- Tissue engineering tools for modulation of the immune response.BioTechniques · 2011Review
- Advancing islet transplantation: from engraftment to the immune response.Diabetologia · 2011Review
- Hydrogels to modulate lentivirus delivery in vivo from microporous tissue engineering scaffolds.Drug delivery and translational research · 2011Article
- Facile DNA immobilization on surfaces through a catecholamine polymer.Angewandte Chemie (International ed. in English) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Tissue engineering scaffolds capable of gene delivery can provide a structure that supports tissue formation while also inducing the expression of inductive factors. Sustained release strategies are hypothesized to maintain elevated plasmid concentrations locally that can enhance gene transfer. In this report, we investigate the relationship between plasmid release kinetics and the extent and duration of transgene expression. Scaffolds were fabricated from polymer microspheres modified with cationic polymers (polyethylenimine, poly(L-lysine), poly(allylamine hydrochloride), polydiallyldimethylammonium) or polydopamine (PD), with PD enhancing incorporation and slowing release. In vivo implantation of scaffolds into the peritoneal fat pad had no significant changes in the level and duration of transgene expression between PD and unmodified scaffolds. Control studies with plasmid dried onto scaffolds, which exhibited a rapid release, and scaffolds with extended leaching to reduce initial quantities released had similar levels and duration of expression. Changing the plasmid design, from a cytomegalovirus (CMV) to an ubiquitin C (UbC) promoter substantially altered the duration of expression. These studies suggest that the initial dose released and vector design affect the extent and duration of transgene expression, which may be sustained over several weeks, potentially leading to numerous applications in cell transplantation and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.